PL3558321T3 - Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b - Google Patents

Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b

Info

Publication number
PL3558321T3
PL3558321T3 PL17883520.3T PL17883520T PL3558321T3 PL 3558321 T3 PL3558321 T3 PL 3558321T3 PL 17883520 T PL17883520 T PL 17883520T PL 3558321 T3 PL3558321 T3 PL 3558321T3
Authority
PL
Poland
Prior art keywords
dyrk1b
dyrk1a
quinolines
kinases
inhibitors
Prior art date
Application number
PL17883520.3T
Other languages
English (en)
Inventor
Agnieszka DREAS
Charles-Henry Fabritius
Andrzej DZIENIA
Anna BUDA
Michał Gałęzowski
Georgiy KACHKOVSKYI
Urszula KULESZA
Katarzyna KUCWAJ-BRYSZ
Agnieszka SZAMBORSKA-GBUR
Wojciech Czardybon
Maria Vilenchik
Michael Frid
Alexandra KUZNETSOVA
Original Assignee
Felicitex Therapeutics, Inc.
Ryvu Therapeutics Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicitex Therapeutics, Inc., Ryvu Therapeutics Spółka Akcyjna filed Critical Felicitex Therapeutics, Inc.
Publication of PL3558321T3 publication Critical patent/PL3558321T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17883520.3T 2016-12-23 2017-12-20 Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b PL3558321T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16460096 2016-12-23
PCT/US2017/067527 WO2018119039A1 (en) 2016-12-23 2017-12-20 Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases

Publications (1)

Publication Number Publication Date
PL3558321T3 true PL3558321T3 (pl) 2023-10-23

Family

ID=57777491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17883520.3T PL3558321T3 (pl) 2016-12-23 2017-12-20 Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b

Country Status (6)

Country Link
US (1) US10577365B2 (pl)
EP (2) EP4183786A1 (pl)
JP (2) JP7134973B2 (pl)
LT (1) LT3558321T (pl)
PL (1) PL3558321T3 (pl)
WO (1) WO2018119039A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183786A1 (en) * 2016-12-23 2023-05-24 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
CN110483508B (zh) * 2019-08-29 2020-05-08 山东大学 化合物、制备方法及在制备GSK-3β抑制剂中的应用
US11884647B2 (en) 2019-10-18 2024-01-30 The Regents Of The University Of California Compounds and methods for targeting pathogenic blood vessels
KR20230003981A (ko) * 2021-06-30 2023-01-06 한국화학연구원 DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
US20230192686A1 (en) * 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
CN120904163A (zh) * 2025-10-09 2025-11-07 北京大学第一医院(北京大学第一临床医学院) 一种喹啉类化合物或其药学上可接受的盐及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005534618A (ja) 2002-03-28 2005-11-17 エーザイ株式会社 神経変性疾患用の、ｃ−ｊｕｎｎ−末端キナーゼ阻害剤としての７−アザインドール
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
CA2560454C (en) * 2004-03-30 2013-05-21 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
EP1828180A4 (en) * 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2012511000A (ja) * 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）の阻害剤
WO2011149950A2 (en) * 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
SG10201505951VA (en) * 2010-07-30 2015-08-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
AU2012230890A1 (en) 2011-03-22 2013-09-26 Amgen Inc. Azole compounds as Pim inhibitors
EP2729465A2 (en) 2011-07-05 2014-05-14 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
JP6017559B2 (ja) * 2011-08-19 2016-11-02 ディアクソンヒットＤｉａｘｏｎｈｉｔ Ｄｙｒｋ１阻害剤およびその使用
WO2014085795A1 (en) * 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
EP4183786A1 (en) * 2016-12-23 2023-05-24 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases

Also Published As

Publication number Publication date
EP3558321A4 (en) 2020-05-27
JP2022166286A (ja) 2022-11-01
WO2018119039A1 (en) 2018-06-28
US20180179199A1 (en) 2018-06-28
JP2020502252A (ja) 2020-01-23
EP3558321B1 (en) 2023-02-01
US10577365B2 (en) 2020-03-03
LT3558321T (lt) 2023-05-10
EP4183786A1 (en) 2023-05-24
EP3558321A1 (en) 2019-10-30
JP7134973B2 (ja) 2022-09-12

Similar Documents

Publication Publication Date Title
IL287518A (en) Dual inhibitors of the vista and pd-1 pathways
IL263163A (en) Pyridines are converted as inhibitors of dnmt1
PL3558321T3 (pl) Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
IL268994A (en) Isoquinolines as inhibitors of HPK1
IL261167A (en) Heteroaryl pad4 inhibitors
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
EP3510040A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
EP3273966A4 (en) Inhibitors of cyclin-dependent kinases
IL259801A (en) ezh2 inhibitors and methods of using them
IL279949A (en) Heterocyclic MCT4 inhibitors
EP3558998A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
IL257061A (en) Inhibitors of ezh2
IL259796A (en) Aza-benzimidazole inhibitors of pad4
PL3313833T3 (pl) Związki i ich zastosowanie w charakterze inhibitorów transferazy n-mirystoilu
IL265062B (en) Heteroaryl carboxamide compounds as ripk2 inhibitors
EP3194377A4 (en) Heterocycle substituted amino-pyridine compounds and methods of use thereof
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3212651A4 (en) Administration of ubiquitin-activating enzyme inhibitor and radiation
PL3362450T3 (pl) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
EP3248979A4 (en) Novel inhibitor of flt3 kinase and use thereof
EP3212650A4 (en) Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
EP3284746A4 (en) Preparation and use of kinase inhibitor
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3433243B8 (en) Novel derivatives and their use as selective inhibitors of caspase-2
IL270703B1 (en) History of Reziquimod